FluoGuide A/S invites investors to Q3 webcast – Clinical progress and the road ahead
News
October 23, 2026
FluoGuide A/S will publish its interim report for Q3 2026 on Thursday, 26 November 2026, followed by a live investor webcast later the same day at 14:00 CET.
CEO Morten Albrechtsen and CFO Ole Larsen will
- present the company’s operational and financial results
- provide an update on key clinical developments, including the US pivotal trial of FG001 in high-grade glioma
- present upcoming milestones
The webcast will be hosted and moderated by Cecilia Hallström from BioStockand will include a live Q&A session, offering investors the opportunity to ask questions directly to the management.
Questions can be asked during the event or submitted in advance by e-mail to redaktion@biostock.se.
Date: Thursday 26 November 2026
Time: 14.00 CET
Please login to the webcast via the following link: https://biostock.se/en/2026/10/fluoguide-comments-on-q3/
A recorded version of the presentation will be available on FluoGuide’s website after the webcast.